Recent developments in cell and gene therapy, in particular the emergence of Chimeric Antigen Receptor (CAR) T-cell immunotherapies, have demonstrated a new therapeutic modality to combat life-threatening diseases. Kymriah® (Novartis) and Yescarta® (Gilead) are the first CAR-T therapies that have been approved by both FDA and EMA. They are autologous therapies, where T-cells are isolated from the patient and engineered in order to express a specific CAR which recognizes and targets cancer cells. The clinical success of these products is driving the need for a consistent and cost effective manufacturing process to meet the lot-sizes required for commercial production. Current T-cell manufacturing and production capabilities are greatly laggi...
Ex vivo genetically-modified cellular immunotherapies, such as chimeric antigen receptor T-cells (CA...
A growing pool of efficacy has ballooned the landscape of engineered T-cell therapy clinical trials ...
Ex vivo genetically-modified cellular immunotherapies, such as chimeric antigen receptor T-cells (CA...
Engineered Chimeric Antigen Receptor (CAR) T-cell products have recently gained FDA and EMA approval...
Autologous chimeric antigen receptor T-cells (CAR T-cells) have been proposed as a possible treatmen...
The use of engineered CAR-T cells in clinical trials has been growing over the last years. The recen...
Cancer therapies leveraging the immune system have been improving the course of disease. T-cell ther...
Chimeric antigen receptor T‐cell (CAR‐T) therapies have proven clinical efficacy for the treatment o...
Chimeric antigen receptor T‐cell (CAR‐T) therapies have proven clinical efficacy for the treatment o...
Chimeric antigen receptor T‐cell (CAR‐T) therapies have proven clinical efficacy for the treatment o...
Chimeric antigen receptor T‐cell (CAR‐T) therapies have proven clinical efficacy for the treatment o...
CAR-T immunotherapies present a novel therapeutic modality for the treatment of various blood tumour...
Cell and gene therapies have demonstrated excellent clinical results across a range of indications w...
The current autologous chimeric antigen receptor (CAR)-T cell therapy products, both commercially ap...
Adoptive cell therapy using chimeric antigen receptor (CAR) T cells has shown immense promise in tre...
Ex vivo genetically-modified cellular immunotherapies, such as chimeric antigen receptor T-cells (CA...
A growing pool of efficacy has ballooned the landscape of engineered T-cell therapy clinical trials ...
Ex vivo genetically-modified cellular immunotherapies, such as chimeric antigen receptor T-cells (CA...
Engineered Chimeric Antigen Receptor (CAR) T-cell products have recently gained FDA and EMA approval...
Autologous chimeric antigen receptor T-cells (CAR T-cells) have been proposed as a possible treatmen...
The use of engineered CAR-T cells in clinical trials has been growing over the last years. The recen...
Cancer therapies leveraging the immune system have been improving the course of disease. T-cell ther...
Chimeric antigen receptor T‐cell (CAR‐T) therapies have proven clinical efficacy for the treatment o...
Chimeric antigen receptor T‐cell (CAR‐T) therapies have proven clinical efficacy for the treatment o...
Chimeric antigen receptor T‐cell (CAR‐T) therapies have proven clinical efficacy for the treatment o...
Chimeric antigen receptor T‐cell (CAR‐T) therapies have proven clinical efficacy for the treatment o...
CAR-T immunotherapies present a novel therapeutic modality for the treatment of various blood tumour...
Cell and gene therapies have demonstrated excellent clinical results across a range of indications w...
The current autologous chimeric antigen receptor (CAR)-T cell therapy products, both commercially ap...
Adoptive cell therapy using chimeric antigen receptor (CAR) T cells has shown immense promise in tre...
Ex vivo genetically-modified cellular immunotherapies, such as chimeric antigen receptor T-cells (CA...
A growing pool of efficacy has ballooned the landscape of engineered T-cell therapy clinical trials ...
Ex vivo genetically-modified cellular immunotherapies, such as chimeric antigen receptor T-cells (CA...